These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3009383)

  • 1. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
    Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO
    J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients.
    Aschan J; Ringdén O; Ljungman P; Lönnqvist B; Ohlman S
    Scand J Infect Dis; 1992; 24(2):143-50. PubMed ID: 1322557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
    Reusser P; Gambertoglio JG; Lilleby K; Meyers JD
    J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.
    Farthing C; Anderson MG; Ellis ME; Gazzard BG; Chanas AC
    J Med Virol; 1987 Jun; 22(2):157-62. PubMed ID: 3039052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
    Ganly PS; Arthur C; Goldman JM; Schulenburg WE
    Postgrad Med J; 1988 May; 64(751):389-91. PubMed ID: 2849092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
    Ahlmén J; Wijnween AC; Brynger H; Lycke E
    Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
    Walmsley SL; Chew E; Read SE; Vellend H; Salit I; Rachlis A; Fanning MM
    J Infect Dis; 1988 Mar; 157(3):569-72. PubMed ID: 2830347
    [No Abstract]   [Full Text] [Related]  

  • 9. Foscarnet for cytomegalovirus infections.
    Ringdén O; Wilczek H; Lönnqvist B; Gahrton G; Wahren B; Lernestedt JO
    Lancet; 1985 Jun; 1(8444):1503-4. PubMed ID: 2861426
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
    Klintmalm G; Lönnqvist B; Oberg B; Gahrton G; Lernestedt JO; Lundgren G; Ringdén O; Robert KH; Wahren B; Groth CG
    Scand J Infect Dis; 1985; 17(2):157-63. PubMed ID: 2992074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foscarnet for cytomegalovirus retinitis.
    Singer DR; Fallon TJ; Schulenburg WE; Williams G; Cohen J
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):962. PubMed ID: 2998255
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of cytomegalovirus infections in immunosuppressed patients].
    Michon C; Girard PM; Ngovan P; Simonpoli AM; Le Hoang P
    Ann Med Interne (Paris); 1988; 139(7):511-5. PubMed ID: 2854380
    [No Abstract]   [Full Text] [Related]  

  • 13. [Importance of Foscarnet in the treatment of cytomegalovirus pneumopathy in a patient with acquired immunodeficiency syndrome].
    Brochard L; Salmeron S; Herve P; Petitpretz P; Boissonnas A; Simonneau G; Duroux P
    Presse Med; 1986 Nov; 15(40):2022-3. PubMed ID: 3025830
    [No Abstract]   [Full Text] [Related]  

  • 14. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
    Jacobson MA; O'Donnell JJ; Mills J
    Antimicrob Agents Chemother; 1989 May; 33(5):736-41. PubMed ID: 2546490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute renal failure induced by foscarnet: 4 cases.
    Cacoub P; Deray G; Baumelou A; Le Hoang P; Rozenbaum W; Gentilini M; Soubrie C; Rousselie R; Jacobs C
    Clin Nephrol; 1988 Jun; 29(6):315-8. PubMed ID: 2840226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
    Drobyski WR; Knox KK; Carrigan DR; Ash RC
    Transplantation; 1991 Jul; 52(1):155-7. PubMed ID: 1650043
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
    MacGregor RR; Graziani AL; Weiss R; Grunwald JE; Gambertoglio JG
    J Infect Dis; 1991 Oct; 164(4):785-7. PubMed ID: 1654363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubulointerstitial nephritis caused by the antiviral agent foscarnet.
    Nyberg G; Svalander C; Blohmé I; Persson H
    Transpl Int; 1989 Dec; 2(4):223-7. PubMed ID: 2560634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapulmonary cytomegalovirus disease in transplant patients.
    Petersen EA
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):13-6. PubMed ID: 1647557
    [No Abstract]   [Full Text] [Related]  

  • 20. Fixed drug eruption due to foscarnet.
    Connolly GM; Gazzard BG; Hawkins DA
    Genitourin Med; 1990 Apr; 66(2):97-8. PubMed ID: 2160425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.